[1] HAN S W, KIM H P, JEON Y K, et al. Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment [J]. Lung Cancer,2008, 61(1):30-34. [2] YOUSEM S A, HOCHHOLZER L. Mucoepidermoid tumors of the lung [J]. Cancer,1987, 60(6):1346-1352. [3] HUO Z, WU H, LI J, et al. Primary pulmonary mucoepidermoid carcinoma: histopathological and moleculargenetic studies of 26 cases [J]. PLoS One, 2015, 10(11):e0143169. [4] ALSIDAWI S, MORRIS J C, WIKENHEISER-BROKAMP K A, et al. Mucoepidermoid carcinoma of the lung: a case report and literature review[J]. Case Rep Oncol Med, 2013,2013:625243. [5] MOLINA J R, AUBRY M C, LEWIS J E, et al. Primary salivary gland-type lung cancer: spectrum of clinical presentation, histopathologic and prognostic factors[J]. Cancer,2007,110(10):2253-2259. [6] XI JJ, JIANG W, LU S H, et al. Primary pulmonary mucoepidermoid carcinoma: an analysis of 21 cases[J]. World J Surg Oncol,2012,1:10:232. [7] OMESH T, GUPTA R, SAQI A, et al. A rare case of endobronchial mucoepidermoid carcinoma of the lung presenting as non-resolving pneumonia[J]. Respir MedCaseRep,2018,25:154-157. [8] SMETANA H F, IVERSON L, SWAN L L. Bronchogenic carcinoma; an analysis of 100 autopsy cases[J]. Mil Surg,1952,111(5):335-351. [9] VASASZ P, EGERVRY M. Mucoepidermoid bronchial tumors: a review of 34 operated cases[J]. Eur J Cardiothorac Surg,2000,17(5):566-569. [10] CURRAN W J, PAULUS R. Sequential vs. concurrent chemoradiation for stage Ⅲ non-small cell lung cancer: randomized phase Ⅲ trial RTOG 9410[J]. J NatlCancerInst,2011,103(19):1452-1460. [11] EL M F, BEN S I, ISMALL O, et al. Mucoepidermoid carcinoma of the lung. A series of 10 cases [J]. Rev Pneumol Clin, 2005,61(2):78-82. [12] MITSUDOMI T, MORITA S, YATABE Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial[J]. Lancet Oncol, 2010,11(2):121-128. [13] CHINNAIYAN P, HUANG S, VALLABHANENI G, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva)[J]. Cancer Res,2005,65(8):3328-3335. [14] JIANG T, MIN W, LI Y, et al. Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis[J]. Cancer Med, 2016,5(6):1055-1065. [15] WANG J, XIA T Y, WANG Y J, et al. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer[J].Int J Radiat Oncol Biol Phys, 2011,81(3):e59-65. [16] OKAAMOTO I, TAKAHASHI T, OKAMOTO H, et al. Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor[J].Lung Cancer, 2011,72(2):199-204. [17] MOSCHINI I, DELL A C, LOSARDO P L, et al. Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors[J]. Future Oncol, 2015,11(16):2329-2342. [18] WANG Y, LI Y, XIA L, et al. Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment[J]. Clin Transl Oncol,2018,20(3):366-373. [19] ZHUANG H, YUAN Z, CHANG J Y,et al. Radiation pneumonitis in patients with non-small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy[J]. J Thorac Oncol, 2014,9(6):882-885. |